Jin Medical International Ltd. (ZJYL)
USD 0.8
(9.59%)
USD 0.8
(9.59%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.91 Million USD | -3.7% |
| 2022 | 4.06 Million USD | 9.07% |
| 2021 | 3.72 Million USD | 18.64% |
| 2020 | 3.14 Million USD | 1.15% |
| 2019 | 3.1 Million USD | -6.79% |
| 2018 | 3.33 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.23 Million USD | -42.88% |
| 2024 Q2 | 1.28 Million USD | 4.16% |
| 2023 Q4 | 2.15 Million USD | 99.02% |
| 2023 FY | 3.91 Million USD | -3.7% |
| 2023 Q1 | 878.44 Thousand USD | -1.94% |
| 2023 Q2 | 1.75 Million USD | 100.29% |
| 2023 Q3 | 1.08 Million USD | -38.37% |
| 2022 Q4 | 895.78 Thousand USD | 0.0% |
| 2022 Q3 | 895.78 Thousand USD | -10.66% |
| 2022 Q2 | 1 Million USD | -0.0% |
| 2022 Q1 | 1 Million USD | -8.07% |
| 2022 FY | 4.06 Million USD | 9.07% |
| 2021 Q4 | 1.09 Million USD | 0.0% |
| 2021 FY | 3.72 Million USD | 18.64% |
| 2021 Q3 | 1.09 Million USD | 47.75% |
| 2021 Q2 | 738.15 Thousand USD | 0.0% |
| 2021 Q1 | 738.15 Thousand USD | -13.83% |
| 2020 Q4 | 856.61 Thousand USD | 0.0% |
| 2020 FY | 3.14 Million USD | 1.15% |
| 2020 Q1 | 659.71 Thousand USD | -24.29% |
| 2020 Q2 | 659.71 Thousand USD | 0.0% |
| 2020 Q3 | 856.61 Thousand USD | 29.85% |
| 2019 Q1 | 809.47 Thousand USD | 0.0% |
| 2019 Q4 | 871.32 Thousand USD | 0.0% |
| 2019 Q2 | 809.47 Thousand USD | 0.0% |
| 2019 Q3 | 871.32 Thousand USD | 7.64% |
| 2019 FY | 3.1 Million USD | -6.79% |
| 2018 FY | 3.33 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 104.27 Million USD | 96.243% |
| AngioDynamics, Inc. | 252.41 Million USD | 98.448% |
| AtriCure, Inc. | 327.05 Million USD | 98.802% |
| Avinger, Inc. | 18.63 Million USD | 78.981% |
| Azenta, Inc. | 336.26 Million USD | 98.835% |
| BioLife Solutions, Inc. | 117.57 Million USD | 96.668% |
| The Cooper Companies, Inc. | 1.82 Billion USD | 99.785% |
| Daxor Corporation | 1.28 Million USD | -205.937% |
| Ekso Bionics Holdings, Inc. | 24.19 Million USD | 83.806% |
| Femasys Inc. | 15.2 Million USD | 74.227% |
| GlucoTrack, Inc. | 7.1 Million USD | 44.854% |
| Harvard Bioscience, Inc. | 58.58 Million USD | 93.313% |
| Hologic, Inc. | 1.34 Billion USD | 99.709% |
| ICU Medical, Inc. | 717.04 Million USD | 99.454% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 99.868% |
| KORU Medical Systems, Inc. | 26.1 Million USD | 84.995% |
| LeMaitre Vascular, Inc. | 90.33 Million USD | 95.663% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 3383.001% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 3383.001% |
| Masimo Corporation | 867 Million USD | 99.548% |
| Microbot Medical Inc. | 9.85 Million USD | 60.248% |
| Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | 78.732% |
| Merit Medical Systems, Inc. | 459.92 Million USD | 99.148% |
| Nephros, Inc. | 9.78 Million USD | 59.959% |
| NovoCure Limited | 613.92 Million USD | 99.362% |
| NEXGEL, Inc. | 4.09 Million USD | 4.356% |
| NEXGEL, Inc. | 4.09 Million USD | 4.356% |
| Singular Genomics Systems, Inc. | 102.24 Million USD | 96.168% |
| OraSure Technologies, Inc. | 125.34 Million USD | 96.874% |
| Pro-Dex, Inc. | 7.37 Million USD | 46.902% |
| Pulse Biosciences, Inc. | 43.57 Million USD | 91.009% |
| Predictive Oncology Inc. | 15.22 Million USD | 74.276% |
| Precision Optics Corporation, Inc. | 8.52 Million USD | 54.03% |
| QuidelOrtho Corporation | 1.35 Billion USD | 99.711% |
| Repligen Corporation | 261.12 Million USD | 98.5% |
| Sanara MedTech Inc. | 61.12 Million USD | 93.591% |
| STAAR Surgical Company | 224.55 Million USD | 98.255% |
| Sharps Technology, Inc. | 10.12 Million USD | 61.314% |
| Utah Medical Products, Inc. | 13.26 Million USD | 70.458% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 99.782% |